Unlike hormone receptor-positive or HER2-positive breast cancers, TNBC lacks common therapeutic targets, such as estrogen receptors or HER2, limiting the effectiveness of conventional targeted therapies. This evidence concerns the gene NR4A1 and breast carcinoma.